Ipsen: Cabometyx in combination with nivolumab shows durable survival benefits at over three-years' follow-up in first-line advanced renal cell carcinoma

Press/Media

Period	13 Feb 2023

Media coverage

Title	Ipsen: Cabometyx in combination with nivolumab shows durable survival benefits at over three-years' follow-up in first-line advanced renal cell carcinoma
Media name/outlet	India Pharma News
Country/Territory	India
Date	13/02/23
URL	ct.moreover.com/?a=50008444348&p=1gw&v=1&x=tEmNyfoF2ZzQPkpTuYZL1g
Persons	Mauricio Burotto